Genscript Biotech Statistics
Total Valuation
Genscript Biotech has a market cap or net worth of HKD 23.25 billion. The enterprise value is 21.06 billion.
Market Cap | 23.25B |
Enterprise Value | 21.06B |
Important Dates
The last earnings date was Friday, November 8, 2024.
Earnings Date | Nov 8, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Genscript Biotech has 2.13 billion shares outstanding. The number of shares has increased by 0.43% in one year.
Current Share Class | n/a |
Shares Outstanding | 2.13B |
Shares Change (YoY) | +0.43% |
Shares Change (QoQ) | +0.22% |
Owned by Insiders (%) | 0.20% |
Owned by Institutions (%) | 17.68% |
Float | 1.16B |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 2.93 |
PB Ratio | 2.45 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -15.24 |
EV / Sales | 2.67 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -9.87 |
Financial Position
The company has a current ratio of 4.15, with a Debt / Equity ratio of 0.54.
Current Ratio | 4.15 |
Quick Ratio | 3.97 |
Debt / Equity | 0.54 |
Debt / EBITDA | n/a |
Debt / FCF | -3.62 |
Interest Coverage | -11.75 |
Financial Efficiency
Return on equity (ROE) is -16.62% and return on invested capital (ROIC) is -7.44%.
Return on Equity (ROE) | -16.62% |
Return on Assets (ROA) | -6.40% |
Return on Capital (ROIC) | -7.44% |
Revenue Per Employee | 1.08M |
Profits Per Employee | -189,751 |
Employee Count | 6,937 |
Asset Turnover | 0.30 |
Inventory Turnover | 9.15 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.93% in the last 52 weeks. The beta is 1.05, so Genscript Biotech's price volatility has been similar to the market average.
Beta (5Y) | 1.05 |
52-Week Price Change | -52.93% |
50-Day Moving Average | 12.09 |
200-Day Moving Average | 12.23 |
Relative Strength Index (RSI) | 38.37 |
Average Volume (20 Days) | 12,778,925 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genscript Biotech had revenue of HKD 7.88 billion and -1.38 billion in losses. Loss per share was -0.65.
Revenue | 7.88B |
Gross Profit | 4.23B |
Operating Income | -2.69B |
Pretax Income | -2.44B |
Net Income | -1.38B |
EBITDA | -2.20B |
EBIT | -2.69B |
Loss Per Share | -0.65 |
Balance Sheet
The company has 14.67 billion in cash and 7.72 billion in debt, giving a net cash position of 6.95 billion or 3.26 per share.
Cash & Cash Equivalents | 14.67B |
Total Debt | 7.72B |
Net Cash | 6.95B |
Net Cash Per Share | 3.26 |
Equity (Book Value) | 14.24B |
Book Value Per Share | 4.46 |
Working Capital | 13.13B |
Cash Flow
In the last 12 months, operating cash flow was -155.29 million and capital expenditures -1.98 billion, giving a free cash flow of -2.13 billion.
Operating Cash Flow | -155.29M |
Capital Expenditures | -1.98B |
Free Cash Flow | -2.13B |
FCF Per Share | -1.00 |
Margins
Gross margin is 53.63%, with operating and profit margins of -34.07% and -17.53%.
Gross Margin | 53.63% |
Operating Margin | -34.07% |
Pretax Margin | -30.90% |
Profit Margin | -17.53% |
EBITDA Margin | -27.95% |
EBIT Margin | -34.07% |
FCF Margin | -27.06% |
Dividends & Yields
Genscript Biotech does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.43% |
Shareholder Yield | -0.43% |
Earnings Yield | n/a |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Genscript Biotech has an Altman Z-Score of 2.04. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.04 |
Piotroski F-Score | n/a |